A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)
Authors
Keywords
-
Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 154, Issue -, Pages 113577
Publisher
Elsevier BV
Online
2022-08-19
DOI
10.1016/j.biopha.2022.113577
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
- (2022) Claudia D. Fuchs et al. Nature Reviews Gastroenterology & Hepatology
- Transcriptional Regulation of Hepatic Autophagy by Nuclear Receptors
- (2022) Eun Young Kim et al. Cells
- Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
- (2022) Veronika A. Prikhodko et al. Biomedicines
- Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
- (2022) Ting-ying Jiao et al. ACTA PHARMACOLOGICA SINICA
- FXR: structures, biology, and drug development for NASH and fibrosis diseases
- (2022) Si-yu Tian et al. ACTA PHARMACOLOGICA SINICA
- Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease
- (2022) Tobias Puengel et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis
- (2022) Takeshi Katafuchi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism
- (2022) Weinan Zhou et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Fibroblast growth factor 15/19 expression, regulation, and function: An overview
- (2022) Greg Guthrie et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Discovery of farnesoid X receptor and its role in bile acid metabolism
- (2022) John Y.L. Chiang et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Transcriptional control of energy metabolism by nuclear receptors
- (2022) Charlotte Scholtes et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Bile acids and their receptors: modulators and therapeutic targets in liver inflammation
- (2022) Anna Bertolini et al. Seminars in Immunopathology
- Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
- (2022) Ryan D. Welch et al. Metabolites
- PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
- (2022) Simona Todisco et al. Biology-Basel
- Review article: vascular effects of PPARs in the context of NASH
- (2022) Sergi Guixé‐Muntet et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice
- (2022) Zhe Zhang et al. Biomedicines
- Gastric Bypass Increases Circulating Bile Acids and Activates Hepatic Farnesoid X Receptor (FXR) but Requires Intact Peroxisome Proliferator Activator Receptor Alpha (PPARα) Signaling to Significantly Reduce Liver Fat Content
- (2021) Guilherme S. Mazzini et al. JOURNAL OF GASTROINTESTINAL SURGERY
- A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
- (2021) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
- (2021) Lulu Sun et al. Nature Reviews Gastroenterology & Hepatology
- Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double‐Blind Phase 2 Trial
- (2021) Samer Gawrieh et al. HEPATOLOGY
- Hepatic SENP2 Controls Systemic Metabolism via SUMOylation‐dependent Regulation of Liver‐Adipose Tissue Crosstalk
- (2021) Yang Liu et al. HEPATOLOGY
- Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis
- (2021) Nikolaos Perakakis et al. LIVER INTERNATIONAL
- Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters
- (2021) François Briand et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Therapeutic aspects of bile acid signalling in the gut‐liver axis
- (2021) Benedikt Simbrunner et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
- (2021) Atsushi Nakajima et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption
- (2021) Bethan L. Clifford et al. Cell Metabolism
- Mechanisms Mediating the Regulation of Peroxisomal Fatty Acid Beta-Oxidation by PPARα
- (2021) Mounia Tahri-Joutey et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Disordered farnesoid X receptor signaling is associated with liver carcinogenesis in Abcb11 ‐deficient mice
- (2021) Liping Wang et al. JOURNAL OF PATHOLOGY
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- (2021) Stephen A. Harrison et al. NATURE MEDICINE
- PPAR control of metabolism and cardiovascular functions
- (2021) David Montaigne et al. Nature Reviews Cardiology
- Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
- (2021) Richard Radun et al. SEMINARS IN LIVER DISEASE
- SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1
- (2021) Chaoyu Zhu et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Hepatic CPT1A Facilitates Liver–Adipose Cross Talk via Induction of FGF21 in Mice
- (2021) Wei Sun et al. DIABETES
- Chiglitazar: First Approval
- (2021) Emma D. Deeks DRUGS
- Novel therapeutic targets for cholestatic and fatty liver disease
- (2021) Michael Trauner et al. GUT
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- (2021) Sven M. Francque et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD
- (2021) Ting Hong et al. Oxidative Medicine and Cellular Longevity
- The pathophysiological function of non-gastrointestinal farnesoid X receptor
- (2021) Nana Yan et al. PHARMACOLOGY & THERAPEUTICS
- Bile Acid Receptors and the Gut–Liver Axis in Nonalcoholic Fatty Liver Disease
- (2021) Rui Xue et al. Cells
- Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
- (2021) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
- (2021) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results
- (2020) K.J. Lucas et al. DIGESTIVE AND LIVER DISEASE
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- NF-кB/HDAC1/SREBP1c pathway mediates the inflammation signal in progression of hepatic steatosis
- (2020) Yunwei Guo et al. Acta Pharmaceutica Sinica B
- PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
- (2020) Yaping Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
- (2020) Philip N. Newsome et al. JOURNAL OF HEPATOLOGY
- Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease
- (2020) Tiangang Li et al. Hepatobiliary Surgery and Nutrition
- Multiple Parallel Hits Hypothesis in NAFLD – Revisited After a Decade
- (2020) Herbert Tilg et al. HEPATOLOGY
- Carbohydrate response element‐binding protein regulates lipid metabolism via mTOR complex1 in diabetic nephropathy
- (2020) Nan Chen et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Focus shifts to antibody cocktails for COVID-19 cytokine storm
- (2020) Charlotte Harrison NATURE BIOTECHNOLOGY
- Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside
- (2020) James J. Beaudoin et al. PHARMACOLOGY & THERAPEUTICS
- Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
- (2020) Anne Fougerat et al. Cells
- Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing
- (2020) Richard Aspinall et al. JOURNAL OF HEPATOLOGY
- Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
- (2020) Sven Francque et al. Nature Reviews Gastroenterology & Hepatology
- Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
- (2020) Stefan Traussnigg et al. WIENER KLINISCHE WOCHENSCHRIFT
- ASBT(SLC10A2): A promising target for treatment of diseases and drug discovery
- (2020) Na Yang et al. BIOMEDICINE & PHARMACOTHERAPY
- Targeting the four pillars of enterohepatic bile salt cycling; lessons from genetics and pharmacology
- (2020) Roni F. Kunst et al. HEPATOLOGY
- FGF19 and FGF21: In NASH we trust
- (2020) Saswata Talukdar et al. Molecular Metabolism
- Ceramides in Metabolism: Key Lipotoxic Players
- (2020) Bhagirath Chaurasia et al. Annual Review of Physiology
- Echinacoside ameliorates alcohol-induced oxidative stress and hepatic steatosis by affecting SREBP1c/FASN pathway via PPARα
- (2020) Zhi Tao et al. FOOD AND CHEMICAL TOXICOLOGY
- Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
- (2020) Yang Xiao et al. Molecular Metabolism
- A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis
- (2020) Mohammad Shadab Siddiqui et al. Clinical Gastroenterology and Hepatology
- A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
- (2019) Steven A. Kliewer et al. Cell Metabolism
- New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
- (2019) Upendra Kaul et al. Cardiovascular Diabetology
- A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
- (2019) Andrea Aloia et al. CLINICAL CANCER RESEARCH
- Hepatocyte peroxisome proliferator-activated receptor α regulates bile acid synthesis and transport
- (2019) Cen Xie et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Immunoregulatory Functions of Nuclear Receptors: Mechanisms and Therapeutic Implications
- (2019) Linjie Zhao et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease
- (2019) Yingfei Xi et al. BIOMEDICINE & PHARMACOTHERAPY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Primary biliary cholangitis: pathogenesis and therapeutic opportunities
- (2019) Aliya F. Gulamhusein et al. Nature Reviews Gastroenterology & Hepatology
- Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury
- (2018) Melina M. Malinen et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Farnesoid X receptor: A “homeostat” for hepatic nutrient metabolism
- (2018) Vittoria Massafra et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway
- (2018) Lichen Bao et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
- (2018) Eiichi Araki et al. DIABETES CARE
- Molecular actions of PPARα in lipid metabolism and inflammation
- (2018) Nadia Bougarne et al. ENDOCRINE REVIEWS
- Na+ -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice
- (2018) Davor Slijepcevic et al. HEPATOLOGY
- Organic solute transporter-β (SLC51B ) deficiency in two brothers with congenital diarrhea and features of cholestasis
- (2018) Mutaz Sultan et al. HEPATOLOGY
- Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid β-oxidation
- (2018) Sunmi Seok et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
- (2018) Christophe Corpechot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of PPARα decreases bile acids in livers of female mice while maintaining bile flow and biliary bile acid excretion
- (2018) Youcai Zhang et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Diet-Induced Circadian Enhancer Remodeling Synchronizes Opposing Hepatic Lipid Metabolic Processes
- (2018) Dongyin Guan et al. CELL
- Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study
- (2018) Jan Oscarsson et al. Journal of Clinical Lipidology
- A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters
- (2018) Mao-xu Ge et al. ACTA PHARMACOLOGICA SINICA
- Gα12 ablation exacerbates liver steatosis and obesity by suppressing USP22/SIRT1-regulated mitochondrial respiration
- (2018) Tae Hyun Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Basal PPARα inhibits bile acid metabolism adaptation in chronic cholestatic model induced by α-naphthylisothiocyanate
- (2018) Huiying Hua et al. TOXICOLOGY LETTERS
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance
- (2017) Geoffrey A. Preidis et al. JOURNAL OF CLINICAL INVESTIGATION
- PPARα protects against trans -fatty-acid-containing diet-induced steatohepatitis
- (2017) Xiao Hu et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- Targeting nuclear receptors for the treatment of fatty liver disease
- (2017) Naoki Tanaka et al. PHARMACOLOGY & THERAPEUTICS
- Editor’s Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner
- (2017) Youcai Zhang et al. TOXICOLOGICAL SCIENCES
- Alteration of Bile Acid and Cholesterol Biosynthesis and Transport by Perfluorononanoic Acid (PFNA) in Mice
- (2017) Yue Zhang et al. TOXICOLOGICAL SCIENCES
- miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
- (2017) Pedro M Rodrigues et al. Cell Death & Disease
- Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
- (2016) Shun Ishibashi et al. ATHEROSCLEROSIS
- Obeticholic Acid: First Global Approval
- (2016) A. Markham et al. DRUGS
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- An Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
- (2016) Frank J. Gonzalez et al. GASTROENTEROLOGY
- Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
- (2016) Alexandra Montagner et al. GUT
- Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice
- (2016) Anuradha Rao et al. Science Translational Medicine
- Fibrates and cholestasis
- (2015) Nisanne S. Ghonem et al. HEPATOLOGY
- PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis
- (2015) Sven Francque et al. JOURNAL OF HEPATOLOGY
- Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
- (2015) Sungsoon Fang et al. NATURE MEDICINE
- Transcriptional regulation of hepatic lipogenesis
- (2015) Yuhui Wang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity
- (2014) Aiming Liu et al. ARCHIVES OF TOXICOLOGY
- Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets
- (2014) Ffolliott M. Fisher et al. GASTROENTEROLOGY
- Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
- (2014) Changtao Jiang et al. JOURNAL OF CLINICAL INVESTIGATION
- Nutrient-sensing nuclear receptors coordinate autophagy
- (2014) Jae Man Lee et al. NATURE
- PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis
- (2014) Xueyan Zhou et al. Nature Communications
- Bile acid receptors in non-alcoholic fatty liver disease
- (2013) Yuanyuan Li et al. BIOCHEMICAL PHARMACOLOGY
- Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1
- (2013) Nasrin Ziamajidi et al. FOOD AND CHEMICAL TOXICOLOGY
- Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis
- (2013) Jiesi Xu et al. HEPATOLOGY
- Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice
- (2012) Bo Kong et al. HEPATOLOGY
- Activation of the Farnesoid X Receptor Induces Hepatic Expression and Secretion of Fibroblast Growth Factor 21
- (2012) Holly A. Cyphert et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism
- (2012) Tian Lan et al. JOURNAL OF HEPATOLOGY
- Metabolomics reveals an essential role for peroxisome proliferator-activated receptor α in bile acid homeostasis
- (2012) Fei Li et al. JOURNAL OF LIPID RESEARCH
- ChREBP Mediates Glucose Repression of Peroxisome Proliferator-activated Receptor α Expression in Pancreatic β-Cells
- (2011) Michael Boergesen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Human SREBP1c Expression in Liver Is Directly Regulated by Peroxisome Proliferator-activated Receptor α (PPARα)
- (2011) Ana Fernández-Alvarez et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genome-Wide Profiling of Liver X Receptor, Retinoid X Receptor, and Peroxisome Proliferator-Activated Receptor in Mouse Liver Reveals Extensive Sharing of Binding Sites
- (2011) M. Boergesen et al. MOLECULAR AND CELLULAR BIOLOGY
- Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease
- (2010) Zhao-Xia Yang et al. Hepatology International
- Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis
- (2009) Sushant Bhatnagar et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
- (2008) C. Fernández-Miranda et al. DIGESTIVE AND LIVER DISEASE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More